Professional Documents
Culture Documents
Combined Salmeterol and Fluticasone in The Treatment of Chronic Obstructive Pulmonary Disease: A Randomised Controlled Trial
Combined Salmeterol and Fluticasone in The Treatment of Chronic Obstructive Pulmonary Disease: A Randomised Controlled Trial
Combined Salmeterol and Fluticasone in The Treatment of Chronic Obstructive Pulmonary Disease: A Randomised Controlled Trial
We obtained approval from local ethics committees at devices. Study drugs were labelled in a way to ensure that
each participating site, and all patients provided written both the patient and the investigator were unaware of the
informed consent. allocated treatment .
During the 2-week run-in, patients stopped taking
Study design regular inhaled corticosteroids or long-acting 2 agonists.
We used a randomised, double-blind, placebo-controlled, Inhaled salbutamol was used as relief medication
parallel-group design. Recruited patients participated in a throughout the study, and regular treatment with
2-week run-in to the trial, a 52-week treatment period anticholinergics, mucolytics, and theophylline was
with clinic visits at weeks 0, 2, 4, 8, 16, 24, 32, 40, and allowed. All non-COPD medications could be continued
52, and a 2-week post-treatment follow-up. if the dose remained constant whenever possible, and if
We used a randomisation schedule generated by the their use would not be expected to affect lung function. If
patient allocation for clinical trials (PACT) program to patients had clinically stable symptoms after 2 weeks, they
assign patients to study treatment groups. Every were randomised to receive one of the following
participating centre was supplied with a list of patient treatments: 50 µg salmeterol and 500 µg fluticasone in
numbers (assigned to patients at their first visit) and a list combination; 50 µg salmeterol; 500 µg fluticasone; or
of treatment numbers. Patients who satisfied the placebo, all twice daily, for 52 weeks via a multidose dry-
eligibility criteria were assigned the next sequential powder inhaler (Diskus or Accuhaler [GlaxoSmithKline,
treatment number from the list. Salmeterol and Greenford, UK]).
fluticasone combination (50/500 µg twice daily), The primary efficacy measure was FEV1 after patients
salmeterol (50 µg twice daily), fluticasone (500 µg twice had abstained from all bronchodilators for at least
daily) and placebo were packaged in identical inhaler 6 h, and from study medication for at least 12 h. Lung-
361 received placebo 372 received salmeterol 374 received fluticasone 358 received salmeterol and
(50 g twice daily) (50 g twice daily) fluticasone combination
(50/500 g twice daily)
221 reached primary 253 reached primary 266 reached primary 269 reached primary
endpoint endpoint endpoint endpoint
For personal use. Only reproduce with permission from The Lancet Publishing Group.
ARTICLES
function tests were done in the clinic: pretreatment FVC, 30 min after inhalation of 400 µg of salbutamol. All
and postbronchodilator FEV1 and FVC were measured at spirometry measurements were done at the same time of
each visit. Postbronchodilator measurements were made day for all patients, with the same spirometer. Every
morning, patients used daily record cards to record the
highest of three peak expiratory flow values measured
Combination treament
with a mini-Wright peak flow meter (Clement Clarke
A Salmeterol
International Harlow, UK) before medication.
200 Fluticasone
Mean change prebronchodilator
Placebo
Every morning, patients recorded the number of times
150
they used relief medication, their symptom scores, and
the number of night-time awakenings for the previous
100 24 h. Symptoms were scored as: breathlessness, 0 (none)
FEV1 (mL)
200 were noted separately. Health status was assessed with the
St George’s Respiratory Questionnaire at weeks 0, 2, 4, 8,
150 24, and 52. In the 22 non-English speaking countries we
used a validated translation of this questionnaire.
100
FEV1 (mL)
Statistical analysis
30
We estimated that a sample size of 300 patients per
(L/min)
Role of the funding source week 2 and was sustained throughout treatment. The
The study sponsor, GlaxoSmithKline, was involved rise in FEV1 associated with combination therapy was
together with the principal investigators in the significantly greater than with either of its components
study design; the collection and analysis of data, which separately (table 2, figure 2). By week 52, pretreatment
was made freely available to all the principal FEV1 in the combination group had increased by 10%
investigators; and the decision to submit the paper for compared with 2% in both the salmeterol and
publication. fluticasone groups, and had fallen by 3% in the placebo
group. We noted the same trend for the other lung-
Results function variables (figure 2). The treatment-by-
We recruited 1974 patients from 196 centres in 25 smoking-status interaction for prebronchodilator FEV1
countries, of whom 1465 received treatment (figure 1). was not significant (p=0·134), indicating that the
Demographic data, baseline characteristics, and difference between the treatment groups was unaffected
compliance did not differ between groups, but the by whether the participant continued to smoke, or not.
withdrawal rate did. Significantly fewer patients Furthermore, the effects of treatment were not biased
withdrew from the combination and fluticasone by unbalanced changes in smoking status between the
groups than from placebo and salmeterol groups treatment groups. During the 12-month study period, a
(table 1). The main reason for differences in withdrawal total of 103 patients (6–7% in each treatment group)
was presence of adverse events. Patients changed their smoking habit, with most of these giving
in the combination group had a slightly higher mean up smoking.
prebronchodilator and postbronchodilator FEV1 and Compared with placebo, all active treatments
fewer mean awakenings per week than did those in significantly reduced the number of exacerbations per
other groups. These minor imbalances in baseline patient per year and the number of exacerbations that
data were accounted for in the statistical analyses needed treatment with oral corticosteroids (table 3).
since both baseline FEV1 and mean night awakenings The rate of exacerbations fell by 25% in the
per week were used as covariates in analyses where combination group (p<0·0001) and by 20% (p=0·0027)
appropriate. and 19% (p=0·0033) in the salmeterol and fluticasone
The three active treatments increased pretreatment groups, respectively, compared with placebo. The
FEV1 significantly compared with placebo (salmeterol/ treatment effect was more pronounced in patients
fluticasone p<0·0001; salmeterol p<0·0001; fluticasone with severe disease (ie, a baseline FEV1 <50% of
p=0·0063; figure 2). This improvement was evident by predicted), who showed a 30% reduction with the
For personal use. Only reproduce with permission from The Lancet Publishing Group.
ARTICLES
For personal use. Only reproduce with permission from The Lancet Publishing Group.
ARTICLES
23 van Elteren P. On the combination of independent two-sample tests and the Chronic Respiratory Disease Questionnaire (CRQ) in a
of Wilcoxon. Bull Int Statist Inst 1960; 37: 351–61. clinical trial setting. Thorax 1999; 54: 995–1003.
24 Hollander M, Wolfe DA. The two-sample location problem. In: 29 Bestall J, Paul E, Garrod R, Garnham R, Jones P, Wedzicha J.
Nonparametric statistical methods, 1st edn. New York: John Wiley Usefulness of the Medical Research Council (MRC) dyspnoea scale
and sons; 1973: 67–82. as a measurement of disability in patients with chronic obstructive
25 Pauwels R, Buist A, Calverley P, Jenkins C, Hurd S. Global strategy pulmonary disease. Thorax 1999; 54: 581–86.
for the diagnosis, management and prevention of chronic obstructive 30 Osman I, Godden D, Friend J, Legge J, Douglas J. Quality of life
pulmonary disease: NHLBI/WHO global initiative for chronic and hospital re-admission in patients with chronic obstructive
obstructive lung disease (GOLD) workshop summary. pulmonary disease. Thorax 1997; 52: 67–71.
Am J Respir Crit Care Med 2001; 163: 1256–76. 31 Knox A, Zhu Y, Pang L. Do long-acting beta2-adrenoceptor
26 Thompson A, Mueller M, Heires A, et al. Aerosolized beclomethasone agonists enhance the anti-inflammatory effect of glucocorticoids in
in chronic bronchitis. Improved pulmonary function and diminished asthma? Eur Respir J 2001; 17: 1059–61.
airway inflammation. Am Rev Respir Dis 1992; 146: 389–95. 32 Dowson L, Newall C, Guest P, Hill S, Stockley R. Exercise capacity
27 Wijkstra P, Ten Vergert E, Van Altena R, et al. Reliability and validity predicts health status in alpha(1)-antitrypsin deficiency.
of the chronic respiratory questionnaire (CRQ). Thorax 1994; 49: Am J Respir Crit Care Med 2001; 163: 936–41.
465–67. 33 Barnes P. Scientific rationale for inhaled combination therapy with
28 Rutten-van Molken M, Roos B, Van Noord J. An empirical long-acting beta2-agonists and oral corticosteroids. Eur Respir J
comparison of the St George’s Respiratory Questionnaire (SGRQ) 2002; 19: 182–91.
Uses of error
The right word
G Burnham
Error is a grim idea, with connotations of bias, importance of epilepsy as a reason for not participating
misjudgment, and increasingly, of liability. Yet the was specifically noted in the verbal instructions to
inadvertent and the fortuitous have given medicine a potential participants.
number of its great successes. Many of the errors noted in After the first round of treatment it became evident
this Lancet series have centred on lessons practitioners that almost no one had been excluded from treatment
have learnt from clinical misjudgments. Fewer have come because of a history of epilepsy. Pursuing this it was
from public health or population-based endeavours. As discovered that the specific word used for epilepsy was
with clinical medicine, these chance occurrences are both not recognised in the study villages even though the
prevalent and underacknowledged. language was the same as in the pilot area where the
When ivermectin was first being tested for effectiveness instructions had been pre-tested. In a hurried follow-up
in onchocerciasis we set out to measure its adverse we identified some 80 persons with epilepsy who had
reactions when given as mass treatment. The three-year been unintentionally treated with ivermectin. Further
study was conducted in an endemic area of Malawi using investigations in this cohort with a history of epilepsy
a double blind, placebo-controlled design. For these revealed that no fits had followed treatment. The cohort
multi-site trials, the World Health Organization had set was then followed through the two subsequent annual
explicit criteria for exclusion of subjects from the study. treatment rounds during which there was no association
Because of the potential for ivermectin to cross the blood- between receiving treatment and having fits. On the basis
brain barrier in mice, it was thought that persons with a of these Malawi findings, a history of epilepsy was
history of epileptic fits should not receive treatment. This dropped as a reason for excluding treatment in the
was an important consideration for us since epilepsy was subsequent ivermectin mass-treatment programmes for
quite common in this part of Malawi, and our hospital onchocerciasis. The outcome from this error of words has
ran a heavily patronised outreach service for its been that tens of thousands of epileptics living in 37
treatment. countries where onchocerciasis is endemic have been
Instructions for potential ivermectin recipients were treated regularly as a prevention against this physically
translated into the vernacular, back translated, and then disabling and potentially blinding disease. This is another
pilot tested in a nearby non-study site for comprehension. reminder that a study may yield important findings aside
Changes were made as necessary to instructions. The from the answering of the original research questions.
The Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, 21205, USA (G Burnham MD)
For personal use. Only reproduce with permission from The Lancet Publishing Group.